Summary.-The study of blocking factors requires a reliable in vitro assay of cell mediated immunity that parallels the in vivo response. By microcytotoxicity testing, progressor and immune peripheral blood lymphocytes caused significant target cell reduction. The cytotoxicity was specific as no cytotoxic effect was detected against unrelated normal as well as malignant target cell lines. No anti-tumour effect was noted when progressor peripheral blood lymphocytes were evaluated in the Winn assay. In marked contrast, immune peripheral blood lymphocytes were capable of preventing tumour growth in the Winn assay. Furthermore, hamsters repeatedly immunized with irradiated SV40 tumour cells could resist a live cell challenge. Thus immune peripheral blood lymphocytes were chosen as the effector population to evaluate the abrogation ability of serum in a microcytotoxicity assay.
Two CONTRASTING effects of serum on attributed to "blocking antibody". More in vitro lymphocytotoxicity have been recent evidence has suggested that the described recently. Serum from animals abrogating factor is an antigen-antibody or cancer patients with progressively complex or soluble tumour specific antigen growing tumours can abrogate the in vitro (Alexander, 1974;  Baldwin, Price and destruction of immune lymphocytes Robins, 1973; Currie and Basham, 1972; (Hellstrom and Hellstrom, 1974) . Init-Currie and Alexander, 1974; Sjogren et al., ially the abrogating effects of serum was 1971). Abrogation of in vitro destruction of cultivated target cells is termed neutralization if it occurs at the effector cell level and blocking if it occurs at the target cell level.
In contrast, non-immune lymphoid cells can induce target cell lysis in vitro in the presence of a specific serum (MacLennan, 1972) . The phenomenon was originally called lymphocyte dependent antibody but is now referred to as cell dependent antibody (Basham and Currie, 1974) or antibody dependent cellular cytotoxicity (DeLandazuri, Kedar and Fahey, 1974) as the effector cell(s) has not been exclusively identified as a lymphocyte. Functionally immune serum can "arm" non-sensitized effector cells (Pollack et al., 1972) or "potentiate" the cytotoxic effect of immune effector cells (Hellstrom et al., 1973) .
The SV40 virus system has been extensively investigated as a model for the study of tumour antigens and immune responses to such antigens (Butel, Tevethia and Melnick, 1971) . While there are data available on the nature of resistance to autochthonous and transplantable tumours Coggin et al., 1974; Deichman and Kluchareva, 1964; Zarling and Tevethia, 1973a, b) in this system, there is little information on the biological role of serum factors in the hamster SV40 system. Girardi (1966) has demonstrated that serum taken from hamsters after interruption of SV40 oncogenesis by SV40 transformed human cells could cause early tumour formation and enhanced tumour growth in normal hamsters. While this study was in progress, Coggin and Anderson (1972) presented data which suggested that both normal and progressor serum could block in vitro cell mediated cytotoxicity. This study was initiated to see if blocking factors were present in the serum of hamsters bearing a transplantable SV40 tumour.
MATERIALS AND METHODS
Hamsters.-Male Syrian golden hamsters (Mesocrecitus auratus) were obtained from High Oaks Ranch, Goodwood, Ontario. The hamsters were maintained on a standard pellet diet and water ad libitum.
Cell lines.-The H50 cell line (supplied by Dr S. S. Tevethia) derived originally from a hamster tumour induced by SV40 virus, synthesizes intranuclear T antigen, surface (S) antigen and SV40 transplantation antigen (Ashkenazi and Melnick, 1963) . When transplanted in vivo to hamsters it causes a rapidly growing fatal tumour. In addition, the SV40 hamster tumour cell lines, F5-1 and LSH (supplied by Dr J. H. Coggin Jr) and the SV40 murine tumour cell line SV-3T3 (supplied by Dr G. Poste) were also used. The BHK21 cell line is a long passaged epithelial line of normal hamster kidney cells which transformed spontaneously in vitro and which causes tumours when transplanted in vivo (MacPherson and Stoker, 1962 Boyum (1968) . The density of the resulting solution was measured with a hydrometer and adjusted with distilled water to 1 079. The solution was filtered through a 0*45 /im millipore membrane and stored at 40C.
Five ml of hamster blood was removed by cardiac puncture with a 6 ml syringe containing 1 ml of 0-05 mol/l ethyl-diaminetetracetic acid. The blood was diluted to 36 ml with serum-free minimal essential medium and 9 ml aliquots of diluted blood were layered on top of 3 ml aliquots of the prepared gradient mixture. The suspension was centrifuged at 700 g for 40 min at room temperature. The upper plasma layer was removed and saved for future washing steps followed by the removal of the mononuclear interface with a Pasteur pipette. The mononuclear cells were washed in a solution containing 15 ml of the plasma layer and 15 ml of fresh serum-free minimal essential medium with 200 ethylene glycol tetracetic acid (EGTA) (Sigma) followed by centrifugation of 300 g for 10 min at 4°C. This washing step was repeated a second time without incorporating 2% EGTA in the serum-free minimal essential medium. Lymphocytes were resuspended in 1 ml of serum-free medium and the concentration ascertained by direct counting in a haemacytometer. Slides for differential white blood cell counts were prepared with the aid of a cytocentrifuge (Shandon, London).
Tunour cell neutralization assay (Winn, 1961 Cytotoxicity assay (Takasugi and Klein, 1970 Mixed Haemadsorption assay.-The mixed haemadsorption assay (MHA) was performed as described by Barth, Espmark and Faggraeus (1967) with modifications for use in the hamster system. Hamster anti-sheep red blood cells (Ha-SRBC (and rabbit anti-hamster gammaglobulin were used in subagglutinating concentrations as previously determined by checkerboard titration.
To prepare the indicator cells equal volumes of 2% SRBC and the designated dilution of Ha-SRBC were mixed and incubated at room temperature for 1 h. The SRBC were washed twice with dextrose-gelatin-veronal buffer (DGV pH 7 0). Equal volumes of sensitized SRBC and an appropriate dilution of rabbit anti-hamster gammaglobulin were mixed and incubated at room temperature for 1 h. The sensitized cells were washed twice in DGV and resuspended in concentrations of 0-1% with 10% MEM.
The target cells growing either in 35 mm Petri dishes (3001, Falcon Plastics) or in wells of microtest plates (3041, Falcon Plastics) were washed twice with 10% MEM before the addition of appropriate dilutions of test sera. They were incubated for 2 h at room temperature and then washed twice with 10% MEM before the addition of the indicator cells. Following a further 1 h incubation the dishes were gently decanted and refilled with medium while the plates were washed 4 times. The dishes were examined under an inverted microscope for adherent red cells indicative of a positive test. The microtest plates were inverted and read on an upright microscope.
In certain experiments, the target cells were pretreated with 0-125% trypsin/PBS pH 7-2 or neuraminidase/0-05 sodium acetate pH 5 5,40 u/ml (Behringwerke, W. Germany) at 37°C for 1 h. The target cells wAere treated as previously described.
Enhancement.-To evaluate the effect of serum on tumour grow,th, serum was collected from hamsters during early, middle and late phases of progressive tumour gromwth. The serum was heat inactivated, clarified by centrifugation (Serofuge II, Clay Adams, Newr York) and 0-2 ml of serum (normal, early, middle, late progressor) was injected intraperitoneally into a group of hamsters. The cytotoxic potential of isolated progressor peripheral blood lymphocytes was evaluated on H50 tumour cells and normal hamster fibroblasts. The results presented in Table I , experiment 1, indicate that at a ratio of 200: 1, progressor lymphocytes caused a significant reduction in the number of surviving H50 target cells but did not reduce the number of normal hamster fibroblasts.
Because of the possibility that the tumour bearers were reacting to antigens associated with the H50 cell line which may have been picked up in culture or other antigens not related to the transformed state, peripheral blood lymphocytes were taken from hamsters bearing tumours which originated in hamsters injected neonatally with SV40 virus and passaged exclusively in vivo. Isolated peripheral blood lymphocytes from hamsters bearing 3 cm tumours taken after the second in vivo passage were tested on H50 and BHK21 target cells at an effector to target cell ratio of 100: 1. As shown in experiment 2 of Table I, significant cytotoxicity was again observed only on the H50 cell line.
Peripheral blood lymphocytes were also taken from hamsters which had been immunized with irradiated H50 cells and tested for cytotoxicity in vitro against H50, BHK21 and normal hamster fibroblasts. The results shown in Table II indicate that significant cytotoxicity was obtained only against the H50 cells. The small degree of cytotoxicity observed on the BHK21 cells was not significant.
W1inn neutralization assay
To obtain further evidence in another system that the in vitro microcytotoxicity assay was reflecting the ability of the effector cells to destroy the target cell in question, we performed experiments using the tumour cell neutralization assay described by Winn (1961) . In these experiments, normal, immune and progressor peripheral blood lymphocytes, isolated in the same manner as for the microcytotoxicity assay, were incubated with H50 tumour cells at an effector to target cell ratio of 100: 1. These mixtures were then injected into the cheek pouch of normal hamsters which were examined weekly for the development of tumours. The results in Table III indicate a marked inhibition of the growth of H50 target cells pre-incubated with immune peripheral blood lymphocytes. This observation is in contrast to the failure of inhibition when the tumour cells were pre-incubated with progressor peripheral blood lymphocytes.
Effect of progressor and post-excision regrowth serum on lymphocyte cytotoxicity Based on the general observation that serum blocking factors can be detected in vitro about the time a tumour becomes palpable and thereafter (Hellstrom and Hellstrom, 1974) , we initially screened progressor serum for blocking activity. The results in Table IV , experiments 1 and 2, indicate that no abrogation of in vitro immune lymphocytotoxicity was obtained with serum from hamsters whose palpable tumour was less than 3 cm in the largest diameter (progressor-middle) and from hamsters whose palpable tumour was greater than 3 cm in size in the largest diameter (progressor-late).
As it may not be possible to detect serum neutralizing activity by the addition of the test serum to the target cells, progressor serum was incubated with the effector cells and then the effector cells were added to the target cells. Again, no abrogation of immune lymphocyte cytotoxicity was observed ( Table IV, Experiments of concomitant tumour immunity (Bashford et al., 1908) were performed as other studies reported that the presence of concomitant tumour immunity correlated with the absence of blocking factors (Deekers et al., 1973; Sjogren and Bansal, 1971) . 104 H50 cells were injected intradermally in the intrascapular area of 32 hamsters and on the following 4 consecutive weeks groups of Table V indicate that hamsters bearing a primary H50 tumour (palpable-2-0 cm size) showed a heightened resistance and not enhanced growth of a secondary challenge compared with normal controls.
Tumour growth enhancement in vivo
The ability of progressor serum to enhance tumour growth in vivo was also evaluated. Hamsters received an intradermal injection of H50 cells, followed by an intraperitoneal injection of one of the following sera: early; middle; late progressor or normal hamster serum. Weekly measurements of tumour size and incidence were recorded. The results (Table VI) do not give any indication of enhanced tumour growth or a large difference in tumour incidence when a comparison is made between the different progressor sera and normal hamster serum.
Effect of progressor (early), immune and post-excision serum on lymphocyte cytotoxicity Classically, tumour immunitv has been demonstrated in models where the animal was immunized with virus or virus transformed cells, or after complete excision of a progressively growing tumour. We wished to determine if immune and postexcision serum had an effect on tumour cell growth in vitro. The results shown in Table VII , experiments 2 and 3 indicate that immune (virus and transplantable) and post-excision sera potentiated the cytotoxic effect of immune effector cells and were also capable of arming normal effector cells. This arming and potentiating effect was also present in progressor serum (early) before the formation of a palpable tumour (Table VII , experiment 1).
Mixed haemadsorption test
The mixed haemadsorption antibody assay was used to determine whether (Howell, Dean and Law, 1975) . The study of Howell et al. (1975) system. This study observed two other effects of serum besides blocking of in vitro lymphocytotoxicity. Thus, besides blocking, each serum had no effect on the specific cell mediated anti-tumour cytotoxic response, or it potentiated the response. The pattern of serum response appears to correlate better with resistance to tumour growth than does the lymphocyte reactivity observed in the microcytotoxicity assay.
Contrary to numerous other animal tumour systems (Hellstrom et al., 1974) , serum blocking factors were not a common occurrence in association with progressive tumour growth in our model. In fact, the only situation where we found serum blocking factors was in those animals who experienced a recurrence of a previously excised tumour. It is important to stress that serum was tested for blocking activity, both at the target and effector cell level. In tests of concomitant tumour immunity enhanced growth in vivo was not seen in animals with progressively growing tumours, nor did serum taken from these animals cause enhanced tumour growth when passively transferred to normal hosts. Unfortunately, we have not been able to perform similar studies with sera demonstrating in vitro blocking activity (post-excision regrowth).
Serum taken from animals with progressively growing tumours neither blocked nor potentiated cell mediated cytotoxicity. The only exception to this was serum taken from animals shortly after inoculation with a clearly tumourigenic number of H50 cells, but before the clinical appearance of tumour. Such sera demonstrated characteristics similar to sera taken from animals rendered immune to tumour transplantation by various procedures. These immune sera augmented the cytotoxic reactivity of tumour immune lymphocytes in vitro (potentiation) (Lamon et al., 1974) and also induced normal lymphocytes to specifically kill tumour cells (arming) (Basham and Currie, 1974) .
The nature of the serum factors involved in these phenomena are not clear from the studies which we have performed to date. No evidence of antibody directed against the tumour cell surface was obtained using mixed haemadsorption tests. The sera alone were not cytotoxic and attempts to lyse the tumour cells with such sera in the presence of complement in classic humoral cytotoxicity assays were unsuccessful (unpublished observations).
There is a strong parallel between those situations in which we have been able to demonstrate an antibody dependent cellular cytotoxicity effect and those in which Ambrose, Anderson and Coggin (1971) demonstrated cytostatic antibody activity. Whether the antibody component of these two phenomena is identical or whether two different parameters of antitumour immunity are involved is not known and requires further study.
Of major importance we feel, is the fact that there appears to be some relevance of the antibody dependent cellular cytotoxicity reaction to the actual tumour host interaction which is not revealed by classic lymphocytotoxicity tests. Thus, progressive primary tumour growth may correlate with a lack of the antibody component of the antibody dependent cellular cytotoxicity response rather than with the presence of a serum blocking factor. A second area of importance is the relative rarity of blocking factors in our model as a feature of progressive tumour growth. Metastasis in this model is a rare and very late event, so that it is conceivable that at least in this system blocking factors may correlate more with the presence of recurrent or metastatic tumour rather than with progressive tumour growth alone. 
